Makar AP - Search Results

1

Endometrial and ovarian malignancies: epidemiology, etiology and prognostic factors.

Makar AP, Tropé CG. Makar AP, et al. Acta Obstet Gynecol Scand. 1992 Jul;71(5):331-6. doi: 10.3109/00016349209021068. Acta Obstet Gynecol Scand. 1992. PMID: 1355947 Review. No abstract available.

2

Unsettled questions regarding ovarian cancer.

Tropé C, Makar A. Tropé C, et al. Acta Obstet Gynecol Scand Suppl. 1992;155:7-18. doi: 10.1111/j.1600-0412.1992.tb00002.x. Acta Obstet Gynecol Scand Suppl. 1992. PMID: 1502893 Review. No abstract available.

3

DNA flow cytometry as a new prognostic factor in ovarian malignancies. A review.

Tropé C, Makar A, Kaern J. Tropé C, et al. Acta Obstet Gynecol Scand Suppl. 1992;155:95-7. doi: 10.1111/j.1600-0412.1992.tb00013.x. Acta Obstet Gynecol Scand Suppl. 1992. PMID: 1502897 Review. No abstract available.

4

Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis.

Makar AP, Kristensen GB, Kaern J, Børmer OP, Abeler VM, Tropé CG. Makar AP, et al. Obstet Gynecol. 1992 Jun;79(6):1002-10. Obstet Gynecol. 1992. PMID: 1579296

5

CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer.

Makar AP, Kristensen GB, Børmer OP, Tropé CG. Makar AP, et al. Gynecol Oncol. 1992 Jun;45(3):323-8. doi: 10.1016/0090-8258(92)90313-8. Gynecol Oncol. 1992. PMID: 1612511

6

Epidemiology, etiology, screening, prevention, and diagnosis in female genital cancer.

Tropé CG, Makar AP. Tropé CG, et al. Among authors: makar ap. Curr Opin Oncol. 1991 Oct;3(5):908-19. doi: 10.1097/00001622-199110000-00016. Curr Opin Oncol. 1991. PMID: 1751582 Review.

7

Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?

Makar AP, Kristensen GB, Børmer OP, Tropé CG. Makar AP, et al. Gynecol Oncol. 1993 Apr;49(1):3-7. doi: 10.1006/gyno.1993.1076. Gynecol Oncol. 1993. PMID: 8482556

8

Fertility preservation in gynecologic cancer.

Makar AP, Tropé C. Makar AP, et al. Acta Obstet Gynecol Scand. 2001 Sep;80(9):794-802. doi: 10.1034/j.1600-0412.2001.080009794.x. Acta Obstet Gynecol Scand. 2001. PMID: 11531628 Free article. Review.

9

Serum CA 125 as a tumor marker and the expression of c-erbB-2 oncogene in tubal malignancies.

Makar AP, Kristensen GB, Nesland J, Børmer OP, Tropé CG. Makar AP, et al. Int J Gynecol Cancer. 1993 Mar;3(2):116-121. doi: 10.1046/j.1525-1438.1993.03020116.x. Int J Gynecol Cancer. 1993. PMID: 11578331

10

The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies.

Makar AP, Holm R, Kristensen GB, Nesland JM, Tropé CG. Makar AP, et al. Int J Gynecol Cancer. 1994 May;4(3):194-199. doi: 10.1046/j.1525-1438.1994.04030194.x. Int J Gynecol Cancer. 1994. PMID: 11578406

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

41 results

Search Page